A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.
Solid Tumor|KRAS Mutation-Related Tumors
DRUG: ZG2001 Tosilate Tablets
Dose Limiting Toxicity (DLT), A DLT is defined as any Grade â‰¥ 3 AE meeting the criteria listed below occurring during the 1st treatment cycle of ZG2001 (Day 1 through Day 21) where the relationship to ZG2001 cannot be ruled out., Up to 21 Days|Incidence of Treatment-Emergent Adverse Events, Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0, Up to 24 Months
This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.